Thursday, May 4, 2017

BRIEF-Fortress Biotech announces final patient dosed in phase 1B trial of cael-101

* Fortress Biotech announces final patient dosed in phase 1b trial of cael-101 for the treatment of al amyloidosis

by reutersCOMPANYNEWS via Endless Supplies .Biz - News
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)